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ABSTRACT
Because of increasing waiting times for adjuvant ra-
diation in the province of Ontario, patients from one
Canadian centre were referred to two centres in the
United States. This situation provided an opportunity
to compare radiation practices.
We performed a retrospective review of radiation
prescribed to patients following breast-conserving sur-
gery for invasive breast cancer. Patients with positive
margins, 4 or more positive lymph nodes, recurrent
disease, or large tumours (>5 cm) were excluded. For
comparison, we reviewed a random sample of similar
patients treated at the Canadian centre during the same
period. A total of 120 referred and 217 non-referred
patients were eligible for comparison. The analysis
included 98 pairs of patients (N = 196), fully matched
on age, nodal status, T stage, grade, and estrogen re-
ceptor (ER) status.
Mean patient age was 60.7 years. The median total
dose and number of fractions differed between cen-
tres [6040 cGy in 32 fractions (United States) vs.
4250 cGy in 16 fractions (Canadian), both p < 0.001).
Boost was used more often in the United States (97%
vs. 9%, p < 0.001). Variation in prescribing patterns
was seen. In the United States, seven different sched-
ules for whole-breast irradiation were used; at the Ca-
nadian centre, two schedules were prescribed.
Predicted radiobiologic effects of these schedules were
calculated to be similar.
Differences in fractionation patterns were observed
between and within U.S. and Canadian centres. Such
variability is likely to affect patient convenience and
resource utilization. Although patient selection, refer-
ring surgeon, and change in policies may account for
some of the observed differences, further research is
necessary to better understand the causes.
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1. INTRODUCTION
Considerable variation in radiation therapy fraction-
ation patterns following breast-conserving surgery
has been documented in several health care re-
gions 1–4. In the past, individual radiotherapy centres
developed their own fractionation regimens empiri-
cally, and those patterns have persisted. In addition,
several pivotal randomized trials that established the
role of breast irradiation following breast-conserv-
ing surgery used various fractionation schedules 5–7.
Few clinical studies that compare fractionation sched-
ules have been performed, but evidence supports the
probable biologic equivalency of the commonly used
schedules with respect to local control and toxic-
ity 4,8,9. Variation in treatment schedules may have a
significant effect on treatment resources 10 and pa-
tient convenience.
Potential sources of variation include standard
schedules that vary between clinics, the training and
preferences of the treating physician, patient prefer-
ence and traveling distance, and resource constraints.
Typically, reports of variation have examined patients
treated in different centres. However, comparison
across centres may be problematic, because patients
are referred from different pools of referring sur-
geons. Differences in local surgical trends may ac-
count for some of the observed variation in radiation
schedules.
In the 1990s, significant delays for radiation
therapy treatment were becoming increasingly rec-
ognized in Canada 11,12. Because of increasing wait-
ing times for breast irradiation in Ontario in early
1999, a process of re-referral to other centres was
developed to expedite care. At the time of consulta-
tion, eligible patients were made aware of extended
wait times and offered referral to another centre, pri-
marily across the border in the United States. Con-
senting patients were referred for a second radiation
oncology consultation at a U.S. centre, where treat-
ment was given. This program provided a unique
opportunity to compare patterns of treatment at vari-
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ous centres in Canada and the United States, among
patients drawn from the same surgical population.
2. MATERIALS AND METHODS
All patients were initially seen for radiation consul-
tation at a single Ontario institution. During the study
period, the annual number of breast cancer patients
being seen for radiation therapy was approximately
700. Patients were referred by surgeons from all com-
munities within the central-west area of Ontario,
where the one institution under study is the only site
for radiation delivery. Limited machine availability
led to extended delays for radiation therapy, and there-
fore all eligible patients were offered re-referral to
participating centres in the United States. The U.S.
centres had previously been selected after site visits
from Ontario radiation oncologists and assessments
of physics quality assurance and clinical activity.
Patients were eligible if they were well enough to
travel independently, were not primary caregivers for
others, and had no distant metastases. Provincial au-
thorities covered the referred patients’ personal costs
for transport and accommodation.
Clinic computer records were used to identify
breast cancer patients who had undergone re-refer-
ral. In addition, a list of breast cancer patients treated
during the same period but not referred to U.S. cen-
tres was obtained. From that list, a random group with
oversampling was chosen to provide a comparison
group. A standardized data collection form was used
to record patient data; surgery and pathology details;
use of systemic treatment; and details of radiotherapy,
including dose, fractionation, energy, use of boost,
and planning technique. Patients were identified
solely by initials and chart number.
Patients were eligible for the comparison group
if they had undergone breast-conserving surgery with
complete resection for early-stage invasive breast
cancer (T1–T2, N0–N1, M0). The referral program
was active from April 1999 until March 2001. Mid-
way through the referral process (July 2000), the U.S.
centres began to treat referred patients according to
the fractionation policy at the Canadian centre, at the
request of Ontario’s provincial cancer organization.
It was felt that inclusion of patients who received
treatment after that date would limit the validity of
the present study’s observations, and so those patients
were excluded. From among the eligible patients, two
groups were created: patients treated in Canada were
paired with patients treated in the United States, fully
matched on five criteria. Those criteria were age cat-
egory (<40 years, 40–70 years, >70 years), axillary
node status (negative, 1–3 nodes positive), T stage
(T1, T2), tumour grade (1, 2, 3), and estrogen recep-
tor (ER) status (positive, negative).
Because of the nonparametric nature of the col-
lected data, the Wilcoxon rank sum test was used to
compare dose and fractionation for whole-breast and
boost irradiation. Matching had maximized the simi-
larity between the two cohorts with respect to prog-
nostic factors. Because of the constant matching ratio
(1:1) and the use of historical cohorts (rather than a
case–control approach), little or no expected loss of
efficiency would occur by breaking the match 13. The
analysis was therefore performed in an unmatched
fashion. Chi-square analysis was used to test differ-
ences in proportions. Conover’s nonparametric test
was used to compare variance 14. The significance
level was set at p < 0.05, two-sided.
3. RESULTS
Details of all eligible referred patients were avail-
able for analysis. Matching on all five pre-selected
criteria (age, T stage, node status, grade, ER status) to
a randomly selected group of patients seen during
the same period but not referred for treatment else-
where resulted in 196 patients available for compari-
son. The patient groups were very similar with respect
to known prognostic factors (Table I).
Comparison of the matched groups revealed dif-
ferences in prescribed radiotherapy with respect to
dose and number of fractions for whole-breast and
boost treatments (Tables II–IV). In the referral group,
seven different whole-breast fractionation schedules
were used; in the comparison group, two different
schedules were used (difference in variance: p <
0.001). Whole-breast doses to patients treated in the
United States ranged from 4000 cGy to 5040 cGy,
and no single fractionation schedule was given to
more than 40% of patients. In the group treated in
Canada, 92% of patients were treated with 4250 cGy
in 16 fractions; all others were treated with 5000 cGy
in 25 fractions. Median prescribed doses were sig-
nificantly higher in the United States [5000 cGy
(range: 4000–5040 cGy) vs. 4250 cGy (range: 4250–
5000 cGy), p < 0.001]. Median number of fractions
TABLE I Clinical characteristics of the matched groups (n=98, each
group)
Characteristic Group
Control Referral
Mean age (years) 60.4 61.1
Mean tumour size (mm) 15.0 13.9
Grade III a (%) 20.4 20.4
Node-negative a (%) 92.9 92.9
ER positive a (%) 86.7 86.7
Left-sided b,c (%) 56.1 45.9
Axillary dissection b (%) 70.4 72.4
Nodes removed ³ 10 b (%) 49.3 47.9
a Matching was done by exact category; therefore percentages are
expected to be identical. See text.
b Not used as a matching criterion.
c p = 0.08; all other comparisons p > 0.1.
ER = estrogen receptor.CROSS-BORDER RADIATION PATTERNS
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given was also higher in the group treated in the
United States [25 fractions (range: 20–28 fractions)
vs. 16 fractions (range: 16–25 fractions), p < 0.001].
Boost irradiation was given in the U.S. centres to
97% of patients, using five different schedules. In
the Canadian centre, only 9% of patients received a
boost, with two schedules being used (p < 0.001).
Again, fractionation patterns were different between
the groups. In patients receiving boost, the median
boost dose delivered was 1400 cGy in the United
States (range: 900–1600 cGy) and 1000 cGy in
Canada (range: 900–1000 cGy). Boost was delivered
over a median of 5 fractions in both centres, but dif-
ferences were observed in the ranges [5–15 fractions
(United States) vs. 4–5 fractions (Canada)].
Median total dose (whole-breast plus boost) was
higher in the group treated in the United States
[6040 cGy (range: 5000–6500 cGy) vs. 4250 cGy
(range: 4250–5250 cGy), p < 0.001], with few pa-
tients receiving less than 6000 cGy (Figure 1). Me-
dian number of prescribed fractions was also higher
in the group treated in the United States [32 fractions
(range: 25–39 fractions) vs. 16 fractions (16–25 frac-
tions), p < 0.001].
4. DISCUSSION AND CONCLUSIONS
Patterns of care for breast cancer have previously been
noted to vary between practice areas 2,4,10. Our re-
port summarizes treatment characteristics in two simi-
lar groups of patients from the same referral base,
treated in different centres in different countries. The
referred cohort treated in the United States was com-
pared to a randomly selected control group of pa-
tients with matched prognostic factors who were
treated in Canada. Findings for the referred group’s
treatment are in keeping with previously reported U.S.
data with respect to whole-breast dose, boost dose,
and proportion of patients receiving boost 15. In the
patients treated in Canada, the median whole-breast
TABLE II Number of patients receiving specified whole-breast frac-
tionation schedules
Schedule Group
(cGy/fractions) Control Referral
4000/20 0 1
4250/16 90 0
4500/25 0 2
4600/23 0 17
4680/26 0 1
4800/24 0 7
5000/25 8 34
5040/28 0 36
TABLE III Boost doses delivered
Dose Group (n a)
(cGy) Control Referral
08 5 1
900 1 1
1000 8 34
1400 0 36
1500 0 21
1600 0 1
a Boost data not available on all 196 patients.
TABLE IV Treatment differences found between groups
Prescription factor Group
Control Referral
Median dose to whole breast [cGy (range)] 4250 (4250–5000) 5000 (4000–5040)
Median boost dose [cGy (range)] a 1000 (900–1000) 1400 (900–1600)
Median total dose [cGy (range)] 4250 (4250–5250) 6040 (5000–6500)
Median fractions to whole breast [n (range)] 16 (16–25) 25 (20–28)
Median boost fractions [n (range)] a 5 (4–5) 5 (5–15)
Median total fractions [n (range)] 16 (16–25) 32 (25–39)
Patients receiving boost (n/N) b 9/98 95/98
Patients receiving loco-regional radiation (n/N) b,c 0/98 7/98
a Median boost dose and fractions only of those patients who received a boost, not the entire group. Therefore, totals do not reflect the sums
of whole-breast and boost numbers.
b Difference tested using Fisher exact test; all others tested using Wilcoxon rank sum test.
c p = 0.01; all other comparisons, p < 0.001.
FIGURE 1 Differences in total dose delivered by each centre.DAYES et al.
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dose was similar to that reported in a previous study
of breast irradiation delivered in Ontario 3.
Several factors may account for the observed dif-
ferences between the groups. Previously identified
factors include local policy, training, patient conve-
nience, and differences in clinical trials supporting
the use of adjuvant breast irradiation 1,10. National
guidelines and resources both likely played a large
part in the radiation schedules seen in the study. The
guideline published in the Canadian Medical Asso-
ciation Journal 16 supports the use of either longer or
shorter fractionation schedules, but recommends
shorter schedules when resources are limited. Al-
though this Canadian guideline does not suggest the
routine use of boost, the National Comprehensive
Cancer Network (NCCN) guideline recommends boost
to the tumour bed. Interestingly, the NCCN guideline
does not discuss fractionation schedules or total
dose 17. Within each centre, adherence to the relevant
national radiotherapy guidelines appears high.
The strength of this study is its homogeneous pool
of patients treated by the same referring surgeons,
available for data collection and matching, with few
missing data, for a unique cross-border comparison.
This common pool of patients served to reduce some
of the limitations identified in previous studies of
breast cancer practice patterns 18. To standardize the
non-randomized comparison groups, inclusion for
analysis was based upon restrictive criteria, with
matching performed on the full set of five pre-selected
prognostic factors. This strict pairing left some
records unmatched, but the final comparison was
based on 196 patients in two very similar groups.
Analysis of all eligible patients (n = 337), including
those not matched, did not alter the study’s findings
(data not shown).
In this study we observed marked differences with
respect to fractionation schedules to the whole breast
and the boost to the primary surgical site. The most
commonly used whole-breast schedule was 42.5 Gy
in 16 fractions in the Canadian centre and 50.4 Gy in
28 fractions in the U.S. centres. Boost irradiation was
infrequently used in the Canadian centre and com-
monly used in the U.S. centres, generally to a higher
dose. We also observed a higher number of different
fractionation schedules in use in the U.S. centres as
compared with the Canadian centre, both to the whole
breast and to the surgical site.
A substantial variation between the centres in the
fractionation schedules used is not surprising. Sev-
eral different schedules were used in the randomized
trials that originally demonstrated the effectiveness
of breast irradiation, and as a result, all of the sched-
ules are considered acceptable for the treatment of
women following breast-conserving surgery.
Interestingly, despite the differences in total dose
and number of fractions between these schedules, all
are predicted to have a similar biologic effect. The
effect of radiation on tumour control and normal tis-
sue is directly related to total dose and fraction size.
Tumour control also appears to be adversely related
to the overall length of treatment, so that shorter treat-
ments are predicted to be more effective. Thus, ra-
diobiologic models suggest that a dose of 50.4 Gy in
28 fractions given over 5.5 weeks is likely to be simi-
lar in effect to a dose of 42.5 Gy in 16 fractions given
over 3 weeks. In this instance, although the overall
dose is lower, the dose per fraction is increased, and
the overall treatment time is shortened by almost 50%.
Recent randomized data support these radiobiologic
models, suggesting that a slightly lower dose given
in 3 weeks is just as effective as a higher dose given
in 5 weeks, both with respect to tumour control and
radiation morbidity in normal tissue 8. Hopefully,
optimal treatments can be determined as more data
become available on the radiobiology of breast tis-
sue and the effect of fractionation 19.
The advantages of the shorter radiation schedule
are primarily patient convenience and cost of treat-
ment where health care is provided by a public sys-
tem, as in Canada. As waiting times grow because of
resource limitations, shorter schedules become more
attractive. In the United States, where health care is
provided both by public and by private systems, re-
sources for radiation are less limited and more easily
accessible; the demand for shorter radiation sched-
ules is less. In Canada, radiation therapy is provided
in regionalized centres, making the therapy less ac-
cessible to patients living in rural areas.
In this study we also observed differences in the
use of boost irradiation to the primary site following
whole-breast irradiation. Again, this finding is not
surprising. The use of boost irradiation in patients
with clear margins of excision following breast-con-
serving surgery has been controversial. It is often
difficult to localize the surgical cavity for additional
radiation, and during the study period, it was unclear
whether such treatment is effective. Boost irradia-
tion has been routinely used in some institutions, but
it was not consistently used in the randomized stud-
ies that established the role of adjuvant breast irra-
diation 6,20. Later, a large European randomized trial
demonstrated that boost irradiation is effective 21. The
benefit appears to be substantial for younger women,
but at the expense of increased morbidity to the skin
and soft tissue, resulting in a decreased cosmetic out-
come. The effect of boost irradiation for older women
appears to be limited. This European trial was not
published before the treatment period evaluated in
the present study. The limited evidence of effective-
ness of boost, in conjunction with limited resources,
probably made boost irradiation less attractive in
Canada. With the publication of the European trial,
that situation has probably changed.
The limitations of our study include its retrospec-
tive nature and its generalizability, which may be lim-
ited because it is based on results from only three
centres (one in Ontario and two in New York State),CROSS-BORDER RADIATION PATTERNS
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rather than on a comparison of the entire province
and the entire state. In addition, comparing a single
institution to two others may have inflated estimates
in differences of variability. There is also concern that
the mere creation of the referral program may have
influenced fractionation practices. For example, re-
ferred patients may have created a resource strain in
the U.S. centres and reduced the strain in the Cana-
dian one, which may have influenced prescribing
patterns and thus potentially limited the differences
observed.
Within a similar patient population, this analysis
revealed several differences in the radiation prescrib-
ing patterns in U.S. and Canadian cancer centres dur-
ing a cross-border referral program designed to
alleviate waiting times for treatment for breast can-
cer. The differences were likely generated by mul-
tiple factors—in particular, physician training,
institutional preference, and adherence to different
national guidelines—and reflect the variation in the
schedules used in the randomized trials that demon-
strated the effectiveness of the treatment. Pressures
from different health care systems were also likely to
influence the choice of fractionation schedule. More
recent randomized trials demonstrated the equiva-
lence of various fractionation schedules and the im-
portance of using boost irradiation in selected patients.
Such studies are likely to have an influence in the
choice of fractionation schedules used both north and
south of the border. Because cross-border referral
programmes may continue to be a strategy to expe-
dite patient care in Canada 22, further study and a
better understanding of these factors may be of value
when creating local policies, allocating health re-
sources, and conducting future clinical studies.
Issues of patient convenience and resource con-
siderations are becoming increasingly important for
all countries as the incidence of early breast cancer
continues to increase because of an aging population
and detection by screening mammography. As a re-
sult, there is increasing interest in shortening treat-
ment schedules even further with the use of
accelerated partial-breast irradiation. The rationale for
this approach is based on the observation that more
local recurrences occur at the primary surgical site.
By limiting treatment to a smaller area, radiation can
be given in shorter treatment periods ranging from
1 day to 1 week. Such treatments are also likely to
be more cost-effective. As a result, the variation in
fractionation schedules used for whole-breast irra-
diation are expected probably to decrease both within
and between different countries over time. Such uni-
formity is desirable for women if it results in more
convenient, more effective, and less costly treatment.
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